Key Highlights

  • Loss was USD 0.06 per share against an estimated USD 0.33 loss, and Revenue of USD 22.2 million beat estimates.
  • Revenue grew 8% year over year, and China revenue rose 31% through the company's distribution partners.
  • Adjusted gross Margin was 57.1% and adjusted EBITDA was USD 1.8 million, a 7.9% margin.
  • Full-year revenue growth guidance of 3% to 5% and an adjusted gross margin target of 57% to 59% were reaffirmed.

Harvard Bioscience (NASDAQ:HBIO) reported a third quarter 2026 loss of USD 0.06 per share, narrower than the USD 0.33 estimated loss. Revenue of USD 22.2 million compared with the USD 21.80 million estimate and was up 8% from a year earlier, which management described as the second consecutive quarter of strong revenue growth.

Management cited strength across key preclinical platforms, with double-digit momentum in products for organoids and fluidics and in newly introduced products. Revenue from its Chinese distribution partners grew 31%.

Adjusted gross margin was 57.1%, at the low end of the company's outlook range, as Demand for some lower-margin legacy products rose, distribution channel contribution increased and China, where margins are lower, remained strong. Adjusted EBITDA was USD 1.8 million, a 7.9% margin, down from USD 2.0 million and a 9.6% margin in the third quarter of 2025.

Operating loss was USD 1.2 million, against Operating Income of USD 0.2 million a year earlier. Adjusted operating income was USD 1.2 million, a 5.3% margin, down from USD 1.5 million and 7.4%. For the nine months, the company reported an operating loss of USD 3.3 million and a net loss of USD 9.0 million.

Guidance and Restructuring

Management reaffirmed full-year 2026 revenue growth guidance of 3% to 5% and an adjusted gross margin target of 57% to 59%. It also guided to EBITDA growth in the fourth quarter at the midpoint of its outlook. The company said its Project Viking restructuring plan is scheduled to generate USD 3 million of cost savings in 2027 and USD 4 million annually after that.

The restructuring plan, initiated in January 2026, was determined during the first quarter to be a triggering event for reviewing the carrying values of Goodwill and other long-lived assets. Restructuring expenses for the nine months were USD 1.2 million, and cash payments were USD 0.5 million.

Management said pharmaceutical and biotechnology preclinical pipelines are expanding ahead of the upcoming Patent cliff, citing an industry forecast of a 7% increase in clinical trial starts in coming years.

Liquidity Disclosure

Cash and cash equivalents were approximately USD 4.9 million at September 30. The filing states management evaluated Going Concern under accounting standard ASC 205-40. It concluded that recurring net losses, negative operating cash flows and a decline in cash do not raise substantial doubt about continuing as a going concern within twelve months of the issuance date, and the statements were prepared on a going concern basis.

The filing's legal proceedings item refers to a note on commitments and contingencies, which states that, after consultation with legal counsel, the company has determined that the ultimate disposition of such proceedings is not anticipated to have a material adverse effect.

Items to Follow

The margin effect of the shift toward distribution and China, progress on restructuring savings, fourth quarter EBITDA against the guided midpoint and the cash balance are the measurable items.